2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
49
Lung Neoplasms
12
Neoplasms
8
Lymphoma, Large-Cell, Anaplastic
8
Neoplasm Metastasis
7
Multiple Myeloma
6
Lymphoma
6
Granuloma, Plasma Cell
4
Colorectal Neoplasms
4
Adenocarcinoma
4
Uveal Melanoma
3
Neuroblastoma
3
Melanoma
3
Hematologic Neoplasms
3
Carcinoma, Renal Cell
3
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Recurrence
2
Glioma
2
Glioblastoma
2
Carcinoma, Squamous Cell
2
Carcinoma, Hepatocellular
2
Carcinoma
2
Breast Neoplasms
2
ALK-positive NSCLC
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Triple Negative Breast Neoplasms
1
Interventions
Bevacizumab
6
Everolimus
4
Sirolimus
2
Lapatinib
2
HDAC-42
2
vistusertib
1
temsirolimus
1
neratinib
1
icotinib
1
emvododstat
1
brolucizumab
1
brigatinib
1
aflibercept
1
Vascular Endothelial Growth Factor A
1
Valproic Acid
1
Sunitinib
1
Magnetic Resonance Imaging
1
Immunoglobulin G
1
Exome
1
Endostatins
1
Doxycycline
1
Disulfides
1
Crizotinib
1
Cetuximab
1
Axitinib
1
Aspirin
1
AZD 6244
1
89Zr-bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neurofibromatosis 2
×
Crizotinib
×
Clear all
NCT04283669
2026-03-13
NF110
University of Alabama at Birmingham
Phase 2
Completed
12 enrolled
5 charts